

Bangladesh

Support for Vaccine: DTP-HepB-Hib This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Bangladesh						
2. Vaccine grant number:	08-BGD-08b-Y, 1115-BGD-04A-X, 1115-BGD-04a-Y, 16-BGD-04a-X, 16-BGD-04a-Y, 17-BGD-04a-X, 18-BGD-04a-X, 1921-BGD-04a-X, 2022-BGD-04a-X						
3. Date of Decision Letter:	30/09/2019						
4. Date of the Partnership Framework Agreement:	24 June 2013						
5. Programme title:	New Vaccine Support (NVS), DTP-HepB-Hib, Routine						
6. Vaccine type:	DTP-HepB-Hib						
7. Requested product presentation and formulation of vaccine:	Penta, 1 dose(s) per vial, LIQUID						
8. Programme Duration:¹	2002-2022						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement)						
	2002-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	271,795,354	9,804,000	11,938,500	9,794,500	-	-	303,332,354
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number	Amount (US\$)				
	2002	n/a	100,000				
	2008	08-BGD-08b-Y	1,287,000				
	Disbursement						
	Disbursement date		Amount (US\$)				
	07 February, 2002		100,000				
	07 August, 2008		1,287,000				
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement)						
Type of supplies to be purchased with Gavi funds	2002-2019	2020	2021				

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

	Number of vaccine doses		7,984,000	-																																										
	Annual Amounts (US\$)	271,795,354	9,804,000	-																																										
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.																																													
14. Self-procurement:	Not applicable																																													
15. Co-financing obligations:	<p>According to the co-financing policy, the Country falls within the group: Preparatory transition phase</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023</th> <th>2024</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>872,500</td> <td>1,241,600</td> <td>2,987,900</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of AD syringes</td> <td>914,000</td> <td>1,300,800</td> <td>3,130,100</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Number of safety boxes</td> <td>10,075</td> <td>14,325</td> <td>34,450</td> <td>-</td> <td>-</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>1,012,005</td> <td>1,440,253</td> <td>3,465,861</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>1,113,000</td> <td>1,583,500</td> <td>3,810,500</td> <td>-</td> <td>-</td> </tr> </tbody> </table>				Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024	Number of vaccine doses	872,500	1,241,600	2,987,900	-	-	Number of AD syringes	914,000	1,300,800	3,130,100	-	-	Number of re-constitution syringes	-	-	-	-	-	Number of safety boxes	10,075	14,325	34,450	-	-	Value of vaccine doses (US\$)	1,012,005	1,440,253	3,465,861	-	-	Total co-financing payments (US\$) (including freight)	1,113,000	1,583,500	3,810,500	-	-
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024																																									
Number of vaccine doses	872,500	1,241,600	2,987,900	-	-																																									
Number of AD syringes	914,000	1,300,800	3,130,100	-	-																																									
Number of re-constitution syringes	-	-	-	-	-																																									
Number of safety boxes	10,075	14,325	34,450	-	-																																									
Value of vaccine doses (US\$)	1,012,005	1,440,253	3,465,861	-	-																																									
Total co-financing payments (US\$) (including freight)	1,113,000	1,583,500	3,810,500	-	-																																									
16. Operational support for campaigns:	Not applicable																																													
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2020 15 May 2020 N/A </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>					Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020 N/A	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																																				
	Due dates																																													
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020 N/A																																													
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat																																													

18. Financial clarifications:	Country shall provide the following clarifications to Gavi*:
Not applicable	
* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.	
19. Other conditions:	
Not applicable	

Signed by,

On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30 September 2019